Highlight
– The MYSTICS Registry studied 1852 newly diagnosed cardiac sarcoidosis (CS) patients and demonstrated the heterogeneity in clinical presentations and outcomes.
– High utilization of advanced imaging (CMR 64%, FDG-PET 82%) facilitated diagnosis, with over half diagnosed clinically without histological confirmation.
– Immunosuppressive therapy was widely used; however, relapse during steroid tapering occurred in 17% over 5 years and was linked to worse outcomes.
– Phenotypic classification (definite, probable, isolated, systemic) revealed distinct prognostic and management implications.
